ArticlePloS one2026
Sustainable liquisolid compact system using fish viscera oil for enhanced dissolution and antioxidant activity of Baicalein.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBaicalein (BA) is a flavonoid with significant pharmacological and antioxidant activities; however, its poor aqueous solubility and high crystallinity limit its dissolution and oral bioavailability. Liquisolid compact technology represents a promising approach for improving the dissolution behavior of poorly soluble drugs.
objectiveThis study aimed to develop a sustainable liquisolid compact formulation of BA using extracted fish viscera oil as a non-volatile solvent and to evaluate its physicochemical characteristics, dissolution behavior, and antioxidant activity.
methodsFish oil was extracted from salmon viscera and used as a liquid vehicle for preparing BA liquisolid compacts using corn starch as a carrier and talc as a coating material. The prepared formulation was characterized using Fourier Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), and Powder X-Ray Diffraction (PXRD) to evaluate drug-excipient interactions and changes in crystallinity. In vitro dissolution studies were conducted using USP apparatus II in phosphate buffer (pH 6.8). Antioxidant activity was assessed using the DPPH radical scavenging assay in a 96-well microplate reader.
resultsFTIR analysis confirmed the absence of chemical incompatibilities between BA and the formulation components. DSC and PXRD analyses demonstrated a significant reduction in the crystalline nature of BA, indicating its transformation into an amorphous or molecularly dispersed state within the liquisolid compact. The liquisolid compact showed a marked improvement in drug dissolution compared with pure baicalein and the physical mixture. Furthermore, the fish oil-BA formulation exhibited enhanced antioxidant activity compared with BA alone.
conclusionThe developed fish oil-based liquisolid compact system significantly improved the dissolution and antioxidant performance of BA. In addition, the use of fish viscera oil provides a sustainable formulation approach by repurposing marine waste into a functional pharmaceutical excipient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.